Showing results (111-120 of 258) with videos related to
Sort By:
Pageof 26
Journal of Hepatology|May 28, 2013
Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapyEiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, et al.Journal of Hepatology|April 2, 2013
Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis CNorihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, et al.Cancer Treatment and Research Communications|February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancerKoichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.Journal of Hepatology|October 27, 2012
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter studyEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Internal Medicine (Tokyo, Japan)|March 21, 2015
Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infectionAkira Kawano, Eiichi Ogawa, Norihiro Furusyo, et al.Journal of Gastroenterology and Hepatology|June 23, 2015
Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infectionEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 4, 2009
Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancerMasaki Kashihara, Koichi Azuma, Akihiko Kawahara, et al.Journal of Gastroenterology and Hepatology|March 18, 2015
Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis CEiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, et al.World Journal of Gastroenterology|March 8, 2006
Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study GroupNorihiro Furusyo, Masaki Katoh, Yuichi Tanabe, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 5, 2003
Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the peripheryShoko Tanaka, Mamoru Harada, Takashi Mine, et al.Pageof 26